Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
109 participants
INTERVENTIONAL
2017-12-21
2021-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their systemic lupus erythematosus (SLE) with JBT-101. JBT-101 is a synthetic endocannabinoid receptor type 2 (CB2) agonist and an activator of the body's normal processes, to resolve innate immune responses without immunosuppression.
* Participants will receive 2 doses of JBT-101 by mouth (three groups of varying doses) or, placebo, for 84 days and will continue to be followed for an additional 28 days. Participant visits to assess endpoints occur on Day 1, then every 2 weeks twice, then every 4 weeks three times, for a total of six visits.
* The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit 1) will be assessed at every visit.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT02955615
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
NCT02349061
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01196091
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
NCT02554019
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JBT-101: 5 mg Twice Daily
Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
JBT-101
Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
JBT-101: 20 mg & Placebo
Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
JBT-101
Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Placebo
Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
JBT-101: 20 mg Twice Daily
Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
JBT-101
Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Placebo + Placebo
Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
Placebo
Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JBT-101
Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Placebo
Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 3 months of treatment with an anti-malarial drug such as hydroxychloroquine or a history of intolerance, contraindication, or unwillingness to take an anti-malarial drug;
* Meets the Safety of Estrogen in Lupus: National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) definition of arthritis (Petri et al., 1999) or mild/moderate arthritis or tendonitis scored as a BILAG B on the updated BILAG 2004;
* Seven-day average of maximum of daily pain Numerical Rating Scale (NRS) scores ≥ 4 out of 10;
* Overlap with polymyositis, systemic sclerosis, Sjögren's syndrome, or rheumatoid arthritis is allowed, if, in the site investigator's judgment, the predominant clinical features are those of Systemic Lupus Erythematosus (SLE);
* Not expected by the site investigator to require a change in potential disease- modifying treatments for SLE from Screening through Visit 6 (Day 112);
* Willing to not start nor stop any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or potential disease-modifying medications or supplements for SLE from Screening through Visit 6 (Day 112), unless a change is recommended by the site investigator or other treating physicians;
* Willing not to use any legal or illegal cannabinoids, including Food and Drug Administration (FDA)-approved cannabinoids or cannabinoid-mimic drugs, or any illegal substance of abuse from Screening through Visit 6 (Day 112);
* If a woman of child-bearing potential, willing to use one of the highly effective (failure rate \< 1% per year) birth control method from Screening through Visit 6 (Day 112) or for 28 ± 3 days after the last dose of study product; and
* Willing to follow instructions, complete study procedures and attend study visits as required by this protocol.
Exclusion Criteria
* A British Isles Lupus Activity Group (BILAG) A score in one or more BILAG domains at Screening;
* Treatment with any intraarticular, intravenous, or intramuscular systemic corticosteroids within 14 days of Screening;
* Treatment with oral prednisone \> 10 mg per day or \> 20 mg every other day (or equivalent dose of another corticosteroid) within 14 days of Screening;
* Increased dose of systemic corticosteroids in the 14 days prior to Screening;
* Treatment with cyclophosphamide or anti-TNFalpha biologic agents within 3 months before Visit 1 (Day 1);
* Treatment with B cell-depleting monoclonal antibodies (rituximab, Ocrelizumab, anti-CD22) within 6 months before Visit 1 (Day 1);
* Treatment with methotrexate, mycophenolate, azathioprine, leflunomide, cyclosporine, belimumab, tacrolimus, or any other immunosuppressive agent not included in 2b.-d. above, when the dose of that immunosuppressive agent has increased within 3 months before Visit 1. Concurrent treatment with any of these medications is allowed as long as the doses have been stable for at least 3 months before Visit 1 (Day 1); or
* Actively listed on an organ transplantation list or have received an organ transplant other than a corneal transplant.
* Significant diseases or conditions other than SLE that may influence response to the study product or safety, such as:
* Active bacterial or viral infection requiring systemic antibiotic or anti-viral treatment within 14 days before Visit 1 (Day 1);
* Acute or chronic hepatitis B or C infection;
* Human immunodeficiency infection (HIV);
* History of active tuberculosis or positive tuberculosis skin or blood test without: 1) completing a course of appropriate treatment; or ) having received at least one month of appropriate treatment prior to Visit 1 (Day 1) and continuing to receive appropriate treatment during the study;
* No elective surgery should be planned from Visit 1 (Day 1) through Visit 6 (Day 112); or
* A history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy greater than one year before Visit 1 (Day 1).
* Significant heart disease as defined by:
* Uncontrollable congestive heart failure, unstable angina, unstable atherosclerotic cardiovascular disease, significant arrhythmia requiring chronic therapy, pulmonary arterial hypertension with dyspnea, disability rated as New York heart Association Grade III or higher, severe systemic hypertension or severe peripheral vascular disease;
* Marked baseline prolongation of QT/QTc interval (i.e. repeated demonstration of a QTc interval ≥ 450 msec for males and ≥470 msec for females);
* History of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT/QTc syndrome); or
* Clinically significant confirmed abnormality, as determined by the site investigator or qualified designee, on 12-lead Electrocardiogram (ECG) at Screening or Visit 1 (Day 1) before dosing.
* History of chronic pain requiring treatment with narcotic analgesia for more than 14 days total within 6 months of baseline. This does not include self-limited pain associated with identifiable events such as surgery;
* Current evidence of alcohol abuse (defined as 4 or more drinks per day on at least 4 days of the week) or history of abuse of illegal and/or legally prescribed drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, or opioids during the 1 year prior to Screening;
* Currently pregnant, breast-feeding, or lactating;
* Any investigational agent within 30 days or five therapeutic half-lives of that agent whichever is longer, before Visit 1 (Day 1);
* Any of the following values for laboratory tests at Screening:
* A positive pregnancy test (also at Visit 1);
* A newly positive QuantiFERON(R) blood test for tuberculosis, without: 1) completing a course of appropriate treatment; or ) having received at least one month of appropriate treatment prior to Visit 1 and continuing to receive appropriate treatment during the study. If the subject has a previous documented positive tuberculosis skin, then this testing does not need to be repeated. If the subject has a documented negative test result within the last year, testing does not need to be repeated, at the discretion of the site investigator.
* Hemoglobin \< 8 g/dL;
* Neutrophils \< 1.0 x 10\^9/L;
* Platelets \< 75 x 10\^9/L;
* Estimated Glomerular Filtration Rate (eGFR) \< 50 ml/min according to Cockcroft-Gault equation;
* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase \> 2.0 x upper limit of normal; or
* Total bilirubin ≥ 1.5 x upper limit of normal.
* Any other conditions that, in the opinion of the site investigator, are clinically significant and may put the subject at greater safety risk, influence response to study product, or interfere with study assessments. When in doubt, the site investigator or qualified designee should discuss the situation with the Protocol Chairs.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Corbus Pharmaceuticals Inc.
INDUSTRY
Autoimmunity Centers of Excellence
OTHER
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meggan Mackay, M.D., M.S.
Role: STUDY_CHAIR
Northwell Health
Robert B. Zurier, M.D.
Role: STUDY_CHAIR
Northwell Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology
La Jolla, California, United States
UCLA Medical Center: Division of Rheumatology
Los Angeles, California, United States
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center
San Francisco, California, United States
Yale University
New Haven, Connecticut, United States
Emory University: Division of Rheumatology
Atlanta, Georgia, United States
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases
Manhasset, New York, United States
New York University Langone Medical Center: Department of Medicine, Division of Rheumatology
New York, New York, United States
Columbia University Medical Center: Department of Medicine, Division of Rheumatology
New York, New York, United States
Bronx-Lebanon Hospital Center: Division of Rheumatology
The Bronx, New York, United States
Duke University
Durham, North Carolina, United States
MetroHealth Medical Center
Cleveland, Ohio, United States
Penn State MS Hershey Medical Center
Hershey, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Temple University
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
National Institute of Allergy and Infectious Diseases (NIAID) website
Division of Allergy, Immunology, and Transplantation (DAIT) website
Autoimmunity Centers of Excellence (ACE) website
Corbus Pharmaceuticals and Clinical Programs in Systemic Lupus Erythematosus
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIAID CRMS ID#: 30147
Identifier Type: OTHER
Identifier Source: secondary_id
DAIT ALE09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.